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Abstract
Background: Balanced decisions about health care interventions require reliable evidence on
harms as well as benefits. Most systematic reviews focus on efficacy and randomised trials, for
which the methodology is well established. Methods to systematically review harmful effects are
less well developed and there are few sources of guidance for researchers. We present our own
recent experience of conducting systematic reviews of harmful effects and make suggestions for
future practice and further research.
Methods: We described and compared the methods used in three systematic reviews. Our
evaluation focused on the review question, study designs and quality assessment.
Results: One review question focused on providing information on specific harmful effects to
furnish an economic model, the other two addressed much broader questions. All three reviews
included randomised and observational data, although each defined the inclusion criteria differently.
Standard methods were used to assess study quality. Various practical problems were encountered
in applying the study design inclusion criteria and assessing quality, mainly because of poor study
design, inadequate reporting and the limitations of existing tools. All three reviews generated a
large volume of work that did not yield much useful information for health care decision makers.
The key areas for improvement we identified were focusing the review question and developing
methods for quality assessment of studies of harmful effects.
Conclusions: Systematic reviews of harmful effects are more likely to yield information pertinent
to clinical decision-making if they address a focused question. This will enable clear decisions to be
made about the type of research to include in the review. The methodology for assessing the quality
of harmful effects data in systematic reviews requires further development.
Background
Systematic reviews are important tools for evidence-based
health care. They are certainly one of the reasons for the
progress that has been made in obtaining reliable evi-
dence on the beneficial effects of interventions. A recent
study of the medical literature, using Medline and the
Cochrane Library, showed that the number of systematic
reviews published has increased dramatically, from a sin-
gle publication in the years 1966 to 1970, to 23 in 1981
to 1985, and 2467 in 1996 to 2000 [1]. Most of the sys-
tematic reviews focused on efficacy or effectiveness. How-
ever, to make a balanced decision about any intervention
it is essential to have reliable evidence on the harms as
well as the benefits. Although the coverage of harmful
effects has increased over time, only 27% of the reviews
published between 1996 and 2000 included any
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on the safety of the intervention reviewed [1]. This is per-
haps unsurprising as many authors of systematic reviews
restrict inclusion to randomised controlled trials (RCTs)
to minimise bias, and harmful effects are often inade-
quately assessed and/or reported in RCTs [2,3]. Another
important reason for the relative lack of reliable evidence
on harmful effects is that RCTs are not always suitable to
evaluate them and other types of study design need to be
considered [4].
The methodology for conducting systematic reviews of
beneficial effects from RCTs is well established, whereas
the methods for systematically reviewing randomised or
observational data on harmful effects are less well devel-
oped and less often used. Only 1.25% of 3604 publica-
tions cited in the 2001 edition of Side Effects of Drugs
(SEDA-24) were systematic reviews [5]. At present
researchers, like us, who conduct systematic reviews have
limited sources of guidance, such as the suggestions
offered by the Cochrane Collaboration [6]. Fortunately,
research into the methodology of incorporating harmful
effects data in systematic reviews is on the increase, from
which we expect more sources of guidance to emerge.
It is not uncommon, even among experienced reviewers,
to assume that the objective of a systematic review of
harmful effects should encompass all known and previ-
ously unrecognised harmful effects and that data from all
types of study design should be sought. We have re-visited
three systematic reviews of drug interventions in which we
had reviewed harmful effects, to evaluate our own recent
experience, identify areas for improvement and to share
our ideas with other researchers undertaking reviews.
Methods
We used three reviews for this study on the basis that they
had been completed recently (between 2001 and 2003)
and that one of us had been the lead reviewer of harmful
effects in each review. The reviews were conducted as
Health Technology Assessments for the National Coordi-
nating Centre for Health Technology Assessment
(NCCHTA) on behalf of the National Institute for Clinical
Excellence (NICE). The reviews, in order of completion,
were: nicotine replacement therapy (NRT) and bupropion
sustained release (SR) for aiding smoking cessation [7],
atypical antipsychotics for schizophrenia [8], and newer
antiepileptic drugs for epilepsy in adults [9].
We described and compared the methods used in each
review and the problems we encountered in applying
those methods. We focused our evaluation on the review
objectives, the inclusion criteria for study design and the
quality assessment of the primary studies. We do not
report on the matter of searching for studies about harm-
ful effects which presents another challenge to those who
conduct systematic reviews [10,11], because exploratory
work following from the reviews described here is under-
way and preliminary results are reported elsewhere
[12,13].
Results
The main components of the three systematic reviews of
harmful effects are described in Table 1. Our evaluation
highlighted the following aspects of the methodology that
could have been improved on and others that require fur-
ther development.
Review objectives
The schizophrenia review objective appeared to be appro-
priate in seeking to determine the incidence of named
outcomes that were considered by health economists to
be most likely to lead to a change in prescribed treatment
[14]. The objectives of the smoking cessation and epilepsy
reviews were very broad in comparison. Given that the
side-effect profiles of the drugs for smoking cessation were
well established, with details available in various pub-
lished standard reference texts [15,16], it would have been
more efficient to focus the review effort on a clear ques-
tion, such as the significance of seizures for bupropion SR
and the cardiovascular effects of nicotine in NRT. The
objective of the review of harmful effects of the antiepilep-
tic drugs did not target clinical decision-making; the sup-
plementary review of harmful effects might have been of
real use to decision makers if we had focused on a crucial
clinical question such as the safety of the drugs in
pregnancy.
Study designs
All three reviews included study designs other than RCTs
to assess harmful effects. The types of non-randomised
studies included for each review reflected differences in
the reviews' objectives, our judgment as reviewers as to
where the most useful data were likely to be found, and
was to some extent pragmatic in terms of the time availa-
ble to complete the reviews. The reviews with the broad
objectives included more non-randomised studies and
more diverse study designs. The schizophrenia and epi-
lepsy reviews specified a minimum size and duration of
study to be included (see table) in an attempt to add data
over and above what was available from the largest and
longest RCTs. Doing this did involve some indetermina-
ble risk of missing important information.
The review of observational studies carried out in the
schizophrenia review was necessary because the pre-deter-
mined harmful effects of interest were known to be under-
reported in RCTs [8]. The inclusion of non-randomised
studies in the smoking cessation review might have tar-
geted observational data on specific questions aboutPage 2 of 6
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were summarised briefly in the Cochrane review. Simi-
larly in the epilepsy review all the adverse events (not just
the most common) reported in the RCTs of clinical effec-
tiveness should have been reviewed before moving on to
observational studies.
Applying the inclusion criteria
Once the inclusion criteria for study design had been
defined, applying them was problematic. Reports of pri-
mary studies rarely described the study design in sufficient
detail. Many of the studies included in the schizophrenia
review purported to be cohort studies but on closer exam-
ination were in fact large case series involving more than
Table 1: Description of the assessment of harmful effects in the three systematic reviews
Review Schizophrenia Smoking cessation Epilepsy
Intervention evaluated 8 atypical antipsychotics. NRT and bupropion SR. 7 newer antiepileptic drugs.
Objective / Scope Review commissioned by the HTA 
programme and an update of the 
HTA report commissioned by NICE. 
The objective regarding harmful 
effects was to determine the 
incidence of specific rare adverse 
events to populate an economic 
model.
Scope provided by NICE: To review 
all known or unknown harmful effects 
that might be associated with the 
interventions.
Scope provided by NICE: To include 
adverse effects in a review of RCTs of 
clinical effectiveness in adults with 
epilepsy. The reviewers undertook a 
supplementary review of serious, rare 
and long-term harmful effects. Serious 
was defined by WHO criteria [25], long-
term as longer than 6 months, and rare 
as defined by the authors of primary 
studies.
Study designs included
Randomised trials RCTs of atypical antipsychotics 
versus alternative drug treatment or 
placebo in schizophrenia.
An existing Cochrane review was 
used as a source of summary data on 
adverse effects from RCTs of 
effectiveness [26].
Studies that assessed safety as the 
primary objective were included in 
the review of primary studies of 
harmful effects. This included RCTs 
that investigated aspects of clinical 
pharmacology that might impact on 
the drugs' tolerability and safety.
The five most commonly reported 
adverse effects were extracted from 
RCTs as part of the review of clinical 
effectiveness in epilepsy.
RCTs in indications other than epilepsy 
and dose comparisons were eligible for 
inclusion in the supplementary review of 
harmful effects.
Non-randomised studies Cohort studies and case series with 
2000 or more participants or at least 
2 years follow-up, and case-control 
studies of any size or duration.
Uncontrolled trials, prospective and 
retrospective observational studies, 
data from adverse events monitoring 
systems (e.g. UK yellow card scheme) 
and case reports.
Non-randomised controlled trials, 
cohort and case-control studies, 
prospective case series and other 
uncontrolled trials, and open-label 
extension phases of trials. More than 300 
participants had to be exposed or 
follow-up more than 6 months unless the 
study objective was to investigate a 
specific adverse effect. Prescription event 
monitoring [27], and post-marketing 
surveillance reports were also included.
Studies identified 6477 items screened, 924 articles 
retrieved, and 223 studies included: 
171 RCTs, 13 cohort studies, 1 case-
control study, 38 case series.
1280 items screened, 353 articles 
retrieved, and 123 studies included: 
25 RCTs, 4 non-randomised 
controlled trials, 30 uncontrolled 
trials, before/after studies or cohort 
studies, 1 case-control study, 9 
surveillance studies, 1 survey, 53 case 
reports or case series.
108 RCTs were included in the review of 
effectiveness, selected from 4211 items 
screened and 887 articles retrieved.
In the supplementary review of harmful 
effects 3884 items were screened, 227 
articles retrieved, and 77 studies 
included: 2 RCTs, 2 non-randomised 
controlled trials, 26 uncontrolled trials, 
14 open-label phases, 25 cohort studies, 
1 case-control study, 4 prescription 
event monitoring studies, 3 post-
marketing surveillance studies.
Quality assessment Quality checklists for various study 
designs provided in CRD Report 4 
were used [28].
The quality checklist for RCTs 
provided in CRD Report 4 [28], and 
checklists for the other study designs 
published elsewhere [29], were used.
Published checklists were used as a 
starting point. Questions were amended 
and others added to capture information 
specifically on the reliability of harmful 
effects data.
Findings of review Very few studies with useful data 
were found, so the economic model 
could not be populated with 
incidence rates of the adverse events 
of interest.
Primarily the findings merely reflected 
the accepted side-effect profiles for 
NRT and bupropion SR. The review 
did not identify any previously 
unknown harmful effects.
The supplementary review of harmful 
effects did identify reports of potential 
adverse effects not reported in the RCTs 
of clinical effectiveness. However, these 
were mostly effects already documented 
in tertiary sources. There was insufficient 
evidence to attribute causality of other 
reported effects to the test drugs.Page 3 of 6
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bupropion SR included in the smoking cessation review
had actually been derived retrospectively from RCTs. How
exactly the 'cohorts' had been established in studies of epi-
lepsy was often unclear in terms of the source population,
eligibility criteria, and selection, or was simply not
reported. Had we, in all three reviews, only included
reports of studies fitting textbook definitions of particular
study designs, virtually all of the primary study reports we
identified would have been excluded. The inclusive
approach we took turned out to be unrewarding.
In the smoking cessation review, in addition to difficulties
with the study design inclusion criteria, application of the
criterion to only include studies in which assessment of
adverse events was the primary objective was problematic
because it involved a high degree of subjective judgment.
Quality assessment
We encountered problems when applying published
checklists in our reviews of harmful effects. The response
to some questions depended on the outcome of interest,
for example, follow-up may have been adequate for the
assessment of the primary (usually a beneficial) outcome
of the study but not for the collection of data on harmful
effects. We also found that published checklists omit key
features such as how harmful effects data were recorded.
In the epilepsy review we were in a position to learn from
the earlier reviews and spent time clarifying the questions
in the checklists so that they would provide information
relevant to the reliability of the harmful effects data. We
also added items pertinent to reports of harmful effects
such as how and when events were recorded and whether
the time at which they occurred during the study was
reported. Although this informed approach was a step in
the right direction, the major hindrance to applying
checklists in all three reviews was inadequate reporting of
the basic design features of the primary studies.
Once the quality criteria had been applied there remained
the challenge of interpreting the results. In our reviews we
described the evidence identified and tabulated the
response to each checklist question for each primary
study. This generated lengthy summaries that had limited
utility. Even comparing validity within study designs (not
across them) we found it impossible to synthesise the
information as all the included studies had methodologi-
cal flaws and features that could not be assessed due to
inadequate reporting. Reaching a decision about which
studies were likely to give the most reliable results was not
straightforward.
Discussion
Our experience of reviewing harmful effects mirrors that
of other researchers in that a significant investment of
effort failed to yield significant new information [6,17].
A focused review question is standard practice for assess-
ing beneficial outcomes in systematic reviews and should
also be so when reviewing harms. Researchers conducting
reviews need to make sure that they address a well-formu-
lated question about harms that are likely to impact on
clinical decisions. Focusing a review question about
harmful effects will not necessarily mean restricting it to
specific adverse events but may mean, for example,
addressing a particular issue such as long-term effects,
drug interactions, or the incidence of mild effects of
importance to patients. If the aim of the research is to look
for previously unrecognised harmful effects, analysis of
primary surveillance data may be more appropriate than
a systematic review [18]. Researchers also need to be
aware that scopes set by external commissioning bodies,
despite having consulted with national professional and
patient organisations, may not be a suitable question to
address in a systematic review. The wisdom of broad and
non-specific questions about harmful effects should be
questioned because the resources, especially time, needed
to do this comprehensively are usually insufficient.
It is important to realise that an unquestioning belief that
observational studies are the best source of harmful effects
data simply because they are not RCTs can be a pitfall. It
is essential to think carefully about the review question
before widening the inclusion criteria to include non-ran-
domised study designs. Some harmful effects, such as very
rare events or those emerging in the long-term, are
unlikely to be addressed adequately in RCTs. But, even if
observational studies are appropriate to the review ques-
tion researchers should be prepared for the difficulty of
interpreting observational study data outweighing the
anticipated benefits.
The importance of quality assessment of RCTs in system-
atic reviews of effectiveness is well established [19], but
debate continues over the usefulness of checklists and
scales. Quality assessment of other study designs in sys-
tematic reviews is far less well developed [20]. Although
the feasibility of creating one quality checklist to apply to
various study designs has been explored [21], and
research has gone into developing an instrument to meas-
ure the methodological quality of observational studies
[22], and a scale to assess the quality of observational
studies in meta-analyses [23], there is as yet no consensus
on how to synthesise information about quality from a
range of study designs within a systematic review. Our
appraisal of our reviews has shown that these difficulties
are compounded when reviewing data on harms.Page 4 of 6
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nate poor from better quality studies of harmful effects.
Levels of evidence hierarchies have several shortcomings.
The hierarchy of evidence is not always the same for all
harmful or beneficial outcomes. For example, an RCT
with adequate internal validity but limited sample size or
follow-up may be a less reliable source of information
about relatively uncommon harmful effects emerging in
the long-term than a large well-conducted cohort study
with many years of follow-up. Another problem with
ranking evidence in a hierarchy is that different dimen-
sions of quality get condensed into a single grade, result-
ing in a loss of information. Furthermore, the dimensions
included in current hierarchies may not be the most
important in terms of reflecting the reliability of a partic-
ular study's findings [24]. Researchers need to clarify a pri-
ori what exactly they need to glean from their quality
assessment of the primary studies in their own review of
harmful effects and it may be necessary to differentiate
clearly between internal and external validity.
We suggest that further research is needed to collate,
assimilate and build on the existing information relevant
to systematically reviewing primary studies for harmful
effects of health care interventions. This should include a
review of the literature pertinent to the methodology of
incorporating evidence of harmful effects in systematic
reviews; a description and categorisation of the methods
used in systematic reviews published to date, and any evi-
dence from methodological research on which they are
based; and the development of quality assessment
methods.
Conclusions
Appraisal of our recent experience highlighted some of the
problems inherent in conducting systematic reviews of
harmful effects of health care interventions. Such reviews
need to address a well-formulated question to facilitate
clear decisions about the type of research to include and
how best to summarise it, and to avoid repeating what is
already known. The review question about harmful effects
needs to be relevant to clinical decision-making. A system-
atic review of the methodology pertinent to systematic
reviews of harmful effects is warranted.
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